Article Text

PDF
Concise report
Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial
  1. A Hartkamp1,2,
  2. R Geenen1,3,
  3. G L R Godaert3,
  4. M Bijl4,
  5. J W J Bijlsma1,
  6. R H W M Derksen1
  1. 1Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
  2. 2Department of Rheumatology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands
  3. 3Department of Clinical & Health Psychology, Utrecht University, Utrecht, The Netherlands
  4. 4Department of Internal Medicine, Division of Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands
  1. Correspondence to Rinie Geenen, Department of Clinical & Health Psychology, Utrecht University, PO Box 80140, 3508TC Utrecht, The Netherlands; r.geenen{at}uu.nl

Abstract

Objective Dehydroepiandrosterone (DHEA) has been reported to improve fatigue and reduced well-being. Both are major problems in patients with systemic lupus erythematosus (SLE), even with quiescent disease. Low serum DHEA levels are common in SLE. The present work investigates the effects of DHEA administration on fatigue, well-being and functioning in women with inactive SLE.

Methods In a double-blind, randomised, placebo-controlled study, 60 female patients with inactive SLE received 200 mg oral DHEA or placebo. Primary outcome measures were general fatigue, depressive mood, mental well-being and physical functioning. Assessments were made before treatment, after 3, 6 and 12 months on medication, and 6 months after cessation of treatment.

Results Patients from the DHEA and placebo group improved on general fatigue (p<0.001) and mental well-being (p=0.04). There was no differential effect of DHEA. The belief that DHEA had been used was a stronger predictor for improvement of general fatigue than the actual use of DHEA (p=0.04).

Conclusions The trial does not indicate an effect of daily 200 mg oral DHEA on fatigue and well-being, and therefore DHEA treatment is not recommended in unselected female patients with quiescent SLE.

Clinical Trials Registration Number NCT00391924

Statistics from Altmetric.com

Footnotes

  • Funding The Dutch Arthritis Association financially supported this study.

  • Competing interests None.

  • Ethics approval This study was conducted with the approval of the institutional review boards of the UMC Utrecht and the UMC Groningen, The Netherlands.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.